FeesSafety
Pluang+

Aura Biosciences advances with strong cash and Phase 3 trial for eye cancer expected in 2027

Market News
31 Oct 2026, 14:33 WIB
Seeking Alpha
View Source
Bullish
Aura Biosciences advances with strong cash and Phase 3 trial for eye cancer expected in 2027

Aura Biosciences is positioned as a low-risk, fully funded company focusing on bel-sar treatment for early choroidal melanoma, with pivotal Phase 3 trial data expected in 2027. The company holds $323.8 million in cash as of June 2026, supporting operations through the first half of 2029 and removing near-term financing concerns. Aura's strategic shift to ocular oncology, leadership changes, and workforce cuts aim to streamline efforts and focus on a niche market with little competition. Despite trading near its cash value, Aura's late-stage asset and strong trial design suggest undervaluation in the market.

Aura Biosciences is the focus of this update, with Pluang providing a snapshot of the health sector market as of Oct 31, 2026, 15:21 WIB. Among 150 health-sector US stocks priced on Pluang, 40 advanced while 108 declined today. Notable movers include ResMed Inc. (RMD) at USD 229.94, down 9.05% with a typical hold time of 52 days, Bruker Corporation (BRKR) at USD 57.07, down 7.95% with a 22-day hold, and Maravai LifeSciences (MRVI) at USD 7.81, down 7.68% with a 12-day hold.

More News

Claims of Curve Finance losing $10B are unverified; current liquidity is $1.11B with no official breach reported.

Claims of Curve Finance losing $10B are unverified; current liquidity is $1.11B with no official breach reported.

A circulating claim that Curve Finance lost $10 billion is unverified with no official announcements or on-chain evidence supporting it. The protocol currently holds about $1.11 billion in liquidity, making a $10 billion loss structurally impossible....

Market News
Bearish
4 hours ago
XRP ETF investors face nearly $489M paper losses despite $1.81B inflows as XRP price lags entry levels.

XRP ETF investors face nearly $489M paper losses despite $1.81B inflows as XRP price lags entry levels.

US spot XRP ETFs have attracted about $1.81 billion in net inflows but now show nearly $489 million in unrealized losses as XRP trades below the average entry price of $1.72. Losses have increased by $113 million in ten days, with Canary Capital's XR...

Market News
Bearish
4 hours ago
XRP Ledger's 100 TPS milestone marks transaction speed, not token price, says Ripple CTO Emeritus.

XRP Ledger's 100 TPS milestone marks transaction speed, not token price, says Ripple CTO Emeritus.

Ripple CTO Emeritus David Schwartz clarified that the "100" on his XRP shirt represents the XRP Ledger's transaction capacity milestone of 100 transactions per second (TPS), not the token's price. The shirt was made to celebrate the XRPL reaching 100...

Protocol Fundamentals
Neutral
4 hours ago
WIF token price rises 3.10% to $0.18 on Oct. 31, reflecting market movement in 24 hours.

WIF token price rises 3.10% to $0.18 on Oct. 31, reflecting market movement in 24 hours.

The WIF token experienced a price increase of 3.10%, reaching $0.18 on October 31. This change reflects the token's market performance over the 24-hour period ending at that time. The report highlights a snapshot of WIF's trading activity, indicating...

Market News
Bullish
4 hours ago
Ethereum options open interest rises to $5.85B with calls dominating but puts lead top daily trades

Ethereum options open interest rises to $5.85B with calls dominating but puts lead top daily trades

Ethereum options open interest increased nearly 10% to $5.85 billion, with daily trading volume at $2.7 billion. Call options hold the majority share of open interest and daily volume, indicating bullish positioning, but the most traded contract was ...

Technical Signals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App